MAPK3 and urothelial carcinoma: This study aimed to assess the expression of CacyBP/SIP, ERK1/2, and p38 in low- and high-grade papillary urothelial carcinoma using immunohistochemical and molecular analyses.<h4>Materials and methods</h4>Tissue samples were obtained from 20 patients with high-grade urothelial carcinoma and 20 patients with low-grade urothelial carcinoma.